DOCSLIB.ORG

Abstractbook.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Abstractbook.Pdf Abstractbook AL02 integral role in the pathophysiology of PTH and CGRP Hypersensitivity to Calcitonin Gene-Related Peptide in antagonism might provide a novel mechanism-based Post-Traumatic Headache attributed to Mild treatment option for PTH. Traumatic Brain Injury: A Randomized Clinical Trial. H. Ashina1, A. Iljazi1, H. Al-Khazali1, C. Christensen1, F. Amin1, M. Ashina1, H. Schytz1 1Danish Headache Center, Neurology, Glostrup, AL05 Denmark A randomised, placebo controlled, double blind trial of the effect of the GLP-1 receptor agonist Exenatide Question: Does CGRP induce headache exacerbations on intracranial pressure in Idiopathic Intracranial with migraine-like features in patients with persistent Hypertension (IIH: Pressure Trial). post-traumatic headache (PTH) attributed to mild J. Mitchell1, J. Walker1, H. Lyons1, K. Brock2, V. Vijay1, A. traumatic brain injury (TBI). Yiangou1, Z. Alimajstorovic1, O. Grech1, G. Tsermoulas3, S. Mollan4, A. Sinclair1 Design: A randomized, double-blind, placebo- 1University of Birmingham, Metabolic Neurology, controlled, 2-way crossover study. Analyses were Birmingham, United Kingdom intention-to-treat. Inclusion criteria were diagnosis of 2University of Birmingham, Institute of Cancer and persistent PTH, mild TBI at least 12 months prior to Genomic Sciences, Birmingham, United Kingdom study inclusion, and age between 18 and 65 years. 3University Hospitals Birmingham NHS Foundation Exclusion criteria were any history of primary headache Trust, Department of Neurosurgery, Birmingham, disorder (except infrequent tension-type headache), United Kingdom any history of whiplash injury or more than one TBI, 4University Hospitals Birmingham NHS Foundation pregnant or nursing women, cardiovascular or Trust, Department of Ophthalmology, Birmingham, cerebrovascular disease, pre-trauma psychiatric United Kingdom disease, and medication-overuse headache. Objectives: Assessing the biological effect of a Interventions: Thirty patients with persistent PTH Glucagon-like Peptide 1 receptor(GLP-1R) agonist on received intravenous infusion of 1.5 µg/min of CGRP or intracranial pressure (ICP) in Idiopathic Intracranial placebo over 20 min on 2 study days. Hypertension(IIH). Main Outcomes and Measures: Difference in incidence Background: Pre-clinical data demonstrates the ability of headache exacerbation with migraine-like features of Exenatide, a GLP-1R agonist, to reduce CSF secretion and difference in area under the curve (AUC) for and ICP. Existing GLP-1R agonists therapies are widely headache intensity scores (0-12 h). used to treat obesity and diabetes(but do not cause hypoglycaemia). Results: Of 34 patients assessed for eligibility, 30 patients were included in the analysis. The mean age Methods: Randomised, placebo controlled, double- was 37 years (SD, 11 years; range, 20 – 59 years), and blind physiology trial of Exenatide in women with the mean weight was 73 kg (range, 50 – 110 kg). active IIH(lumbar puncture pressure >25 cmCSF and Twenty-one of 30 participants (70%) developed papilloedema). headache exacerbation with migraine-like features Telemetric, intraparenchymal ICP monitors were after CGRP compared to six participants (20%) after implanted to enable gold standard, long-term ICP placebo (P < 0.001). The baseline corrected AUC for monitoring(Raumedic p-Tel, Helmbrechts, Germany). headache intensity was significantly larger after CGRP Participants were randomised 1:1 to receive compared to placebo (AUC0-12 h, P < 0.001). The median Exenatide(10mcg twice daily sub-cutaneous) or time to peak headache intensity was 120 min (range: placebo for 12 weeks. ICP and weight were recorded 20 – 660 min) after CGRP and 300 min (range: 10 – 600 over a 24-hour baseline visit, at 2 weeks and 12 weeks. min) after placebo (P = 0.509). Monthly headache diaries were completed at baseline and 8-12weeks. No other ICP modulating drugs were Conclusions: PTH patients exhibit hypersensitivity to taken during the study. CGRP infusion which suggests that CGRP plays an 2 Results: Of the 16 participants recruited 15 were ± 1.40 ng/ml, n=10) showed significantly reduced tear randomised and completed the study: age 29.5±9.5, fluid CGRP levels compared to CH patients with no BMI 38.1±6.2 kg/m2, ICP 23.5 ±3.9 mmHg(30.6 cmCSF). intake of acute medication (p=0.022), and their tear All ICP implants were well tolerated and enabled fluid CGRP levels were not significantly different from successful ICP quantification after drug dosing. At healthy controls (p=0.484). No significant difference in baseline participants had median(IQR) Frisen grade tear fluid CGRP levels between episodic 2(1) papilloedema, perimetric mean deviation - (1.48±1.68ng/ml) and chronic CH patients (1.60±1.63 1.76±1.93dB, headache severity 4.64±1.79(numeric ng/ml, p=0.535) was detected. In constrast to these rating scale 0-10) and monthly headache days results in tear fluid samples, there were no significant 17.3±8.19. The primary outcomes(ICP at 2.5hrs, 24hrs differences in plasma CGRP levels between groups. and 12 weeks) are presented at EHF Berlin 2020. Conclusion: To the best of our knowledge, this study Conclusions: We report the first human study to assess shows for the first time that CH patients (chronic or the biological effect of the GLP-1 agonist exenatide on episodic within bout) have increased CGRP levels in ICP in IIH utilising highly accurate implantable tear fluid compared to healthy subjects, which are telemetric ICP monitors. ICP telemetric monitoring was reduced to control levels after intake of a triptan. safe and well tolerated and provides new insights into Detection of CGRP in tear fluid is non-invasive, and drug effects on ICP. New therapies for ICP modulation likely allows a more direct access to CGRP released in IIH are a significant un-met need in this population from the trigeminal nerve than plasma sampling. with escalating incidence. AL07 AL06 Quantification of facial microvascular blood flow in Calcitonin gene-related peptide levels in tear fluid are cluster headache using laser speckle contrast imager: elevated in cluster headache patients compared to Differences between episodic and chronic cluster healthy controls headache K. Kamm1, R. Ruscheweyh1, A. Straube1 A. Andreou1,2, M. Murphy2, B. Hill2, R. 1University Hospital of Munich, Neurology, Munich, AbuukarAbdullahi1, A. Al-Kaisy3, G. Lambru2 Germany 1King's College London, Headache Research, Wolfson CARD, Institute of Psychiatry, Psychology & Background: Calcitonin gene-related peptide (CGRP) Neuroscience, , London, United Kingdom released from trigeminal nerve fibres indicates 2Guy's and St thomas' NHS Foundation Trust, Headache trigeminal activation and has a key role in cluster Centre, London, United Kingdom headache pathophysiology. The trigeminal nerve 3Guy's and St thomas' NHS Foundation Trust, Pain directly innervates the eye. In this study, we compared Management and Neuromodulation Centre, London, CGRP in tear fluid of cluster headache (CH) patients United Kingdom and healthy controls. Aim: To evaluate facial microcirculatory changes, as an Methods: CGRP concentrations in tear fluid and indicator of autonomic system dysregulation using a plasma of 16 episodic (within bout) and 11 chronic CH laser speckle contrast imager interictally in episodic patients and 48 controls were assessed using ELISA. (ECH) in- and outside a bout and in chronic cluster headache (CCH) patients. Results: CH patients without use of triptans in the last 48h (1.78±1.57ng/ml, n=17) showed significantly Methods: Changes in facial blood flow blinded to the higher tear fluid CGRP levels compared to healthy side of the headache were measured in consecutive controls (0.75±0.80ng/ml, p=0.001). High CGRP levels 114 cluster patients (CCH: N=54; ECH: N=60). The mean in CH patients were independent of the recent perfusion rate of both ipsilateral and contralateral occurence of a CH attack (no attack in last 48h: trigeminal territories were calculated. Mann-Whitney 1.95±1.65 ng/ml, n=8; attack in last 48h: 1.63±1.59 test was used for within group comparisons and ng/ml, n=9, p=0.82) as long as no acute medication was Pearson’s correlation was applied for measuring the used. CH patients with triptan use in the last 48h (0.84 association between variables. 3 Results: Nine patients were excluded because of side month post-treatment follow-up (PTFU) period. Safety alternating attacks. In the ECH group in bout, there was outcomes included adverse events, discontinuations, an increased microcirculation on the ipsilateral V1-V2 laboratory values, vital signs, ECG, & suicidality ratings trigeminal territories compared to the corresponding (Columbia Suicide Severity Rating Scale [C-SSRS]). contralateral territories (N=27; V1: 19±2.8%, P<0.001; V2: 20.1±4.2%, P<0.001). The cluster side could be Results: 237 patients entered CGAM, 230 completed predicted in 25/27 patients by the operator (r=0.85, DBL phase, 229 entered OLE (116 PBO, 113 GMB), 152 P<0.001). In contrast, ECH patients outside a bout had (66%) completed OLE, & 148 (65%) completed all study no significant differences in blood flow between the phases. In total, 233 patients received ≥1 dose of GMB, ipsilateral and contralateral sides (N=29; P≥0.53). with a mean exposure to GMB of 341 days. GMB- Amongst CCH, 16/49 had decreased, and 33/49 had treated patients were mostly male (73%), with a mean increased microvascular blood flow in the ipsilateral V1 age of 45 (±11) years. 22% reported history of suicidal and V2 regions. The cluster side could not be predicted ideation. 4% reported history of suicidal behavior. No in CCH (r=0.05, P=0.7). Among all patients, ipsilateral deaths were reported in CGAM. 185 patients (79%) microvascular blood flow increase correlated reported treatment-emergent adverse events (TEAEs), significantly with the time (days) since the last cluster 23 (9.9%) reported serious AEs (SAEs), & 18 (7.7%) attack (r=0.23, P=0.02). discontinued due to an AE. Cluster headache was the only SAE reported by >1 patient (n=3).
Load more

Recommended publications
  • Analysis of Drugs Manual September 2019
    Drug Enforcement Administration Office of Forensic Sciences Analysis of Drugs Manual September 2019 Date Posted: 10/23/2019 Analysis of Drugs Manual Revision: 4 Issue Date: September 5, 2019 Effective Date: September 9, 2019 Approved By: Nelson A. Santos Table of Contents CHAPTER 1 – QUALITY ASSURANCE ......................................................................... 3 CHAPTER 2 – EVIDENCE ANALYSIS ......................................................................... 93 CHAPTER 3 – FIELD ASSISTANCE .......................................................................... 165 CHAPTER 4 – FINGERPRINT AND SPECIAL PROGRAMS ..................................... 179 Appendix 1A – Definitions ........................................................................................... 202 Appendix 1B – Acronyms and Abbreviations .............................................................. 211 Appendix 1C – Instrument Maintenance Schedule ..................................................... 218 Appendix 1D – Color Test Reagent Preparation and Procedures ............................... 224 Appendix 1E – Crystal and Precipitate Test Reagent Preparation and Procedures .... 241 Appendix 1F – Thin Layer Chromatography................................................................ 250 Appendix 1G – Qualitative Method Modifications ........................................................ 254 Appendix 1H – Analytical Supplies and Services ........................................................ 256 Appendix 2A – Random Sampling Procedures
    [Show full text]
  • Cannabigerol Is a Potential Therapeutic Agent in a Novel Combined Therapy for Glioblastoma
    cells Article Cannabigerol Is a Potential Therapeutic Agent in a Novel Combined Therapy for Glioblastoma Tamara T. Lah 1,2,3,*, Metka Novak 1, Milagros A. Pena Almidon 4, Oliviero Marinelli 4 , Barbara Žvar Baškoviˇc 1, Bernarda Majc 1,3, Mateja Mlinar 1, Roman Bošnjak 5, Barbara Breznik 1 , Roby Zomer 6 and Massimo Nabissi 4 1 Department of Genetic Toxicology and Cancer Biology, National Institute of Biology, 1000 Ljubljana, Slovenia; [email protected] (M.N.); [email protected] (B.Ž.B.); [email protected] (B.M.); [email protected] (M.M.); [email protected] (B.B.) 2 Faculty of Chemistry and Chemical Technology, University of Ljubljana, 1000 Ljubljana, Slovenia 3 Jožef Stefan International Postgraduate School, 1000 Ljubljana, Slovenia 4 School of Pharmacy, Experimental Medicine Section, University of Camerino, 62032 Camerino, Italy; [email protected] (M.A.P.A.); [email protected] (O.M.); [email protected] (M.N.) 5 Department of Neurosurgery, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia; [email protected] 6 MGC Pharmaceuticals d.o.o., 1000 Ljubljana, Slovenia; [email protected] * Correspondence: [email protected]; Tel.: +386-41-651-629 Simple Summary: Among primary brain tumours, glioblastoma is the most aggressive. As early relapses are unavoidable despite standard-of-care treatment, the cannabinoids delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) alone or in combination have been suggested as a combined treatment strategy for glioblastomas. However, the known psychoactive effects of THC hamper its medical applications in these patients with potential cognitive impairment due to the progression of the Citation: Lah, T.T.; Novak, M.; Pena Almidon, M.A.; Marinelli, O.; disease.
    [Show full text]
  • A Dissertation Entitled Uncovering Cannabinoid Signaling in C. Elegans
    A Dissertation Entitled Uncovering Cannabinoid Signaling in C. elegans: A New Platform to Study the Effects of Medicinal Cannabis By Mitchell Duane Oakes Submitted to the Graduate Faculty as partial fulfillment of the requirements for the Doctor of Philosophy Degree in Biology ________________________________________ Dr. Richard Komuniecki, Committee Chair _______________________________________ Dr. Bruce Bamber, Committee Member ________________________________________ Dr. Patricia Komuniecki, Committee Member ________________________________________ Dr. Robert Steven, Committee Member ________________________________________ Dr. Ajith Karunarathne, Committee Member ________________________________________ Dr. Jianyang Du, Committee Member ________________________________________ Dr. Amanda Bryant-Friedrich, Dean College of Graduate Studies The University of Toledo August 2018 Copyright 2018, Mitchell Duane Oakes This document is copyrighted material. Under copyright law, no parts of this document may be reproduced without the expressed permission of the author. An Abstract of Uncovering Cannabinoid Signaling in C. elegans: A New Platform to Study the Effects of Medical Cannabis By Mitchell Duane Oakes Submitted to the Graduate Faculty as partial fulfillment of the requirements for the Doctor of Philosophy Degree in Biology The University of Toledo August 2018 Cannabis or marijuana, a popular recreational drug, alters sensory perception and exerts a range of medicinal benefits. The present study demonstrates that C. elegans exposed to
    [Show full text]
  • Microgram Journal, Vol 2, Number 1
    Washington, D. C. Office of Science and Education Vol.II,No.1 Division of Laboratory Operations January 1969 INDEXISSUE CORRECTION 11 "Structure Elucidation of 'LBJ' , by Sander W. Bellman, John W. Turczan, James Heagy and Ted M. Hopes, Micro­ Gram .!., 3, 6-13 (Dec. 1968) Page 7, third and fourth sentences under Discussion: Change to read: "The melting point of the acid moiety found in step (g) was 148-150°c., compared to the litera­ ture, v~lue of 151°c for the melting point of benzilic acid (2); thus the benzilic acid melting point gives support to the proposed structure for 'LBJ'. Spectral evidence also supports the proposed structure". MICRO-GRAMREVISION Please re-number the pages of your copies of Micro-Gram, Volume I. Re-number pages bearing printing only. Vol­ ume I will then be numbered from page 1, the front page of issue No. 1, through page 189 the last page of issue No. 12. To help with this task, pages contained within each issue are as follows: Issue Number Page Through 1 1 8 2 9 29 3 30 32 4 33 66 5 67 79 6 80 97 7 98 120 8 121 128 9 129 136 10 137 157 11 158 170 12 171 189 CAUTION: Use of this publication should be restricted to forensic analysts or others having a legitimate need for this material. From the Archive Library of Erowid Center http://erowid.org/library/periodicals/microgram -2- CANNABIS ,·,-...__/' Attached is a copy of 11A Short Rapid Method for the Identification of Cannabis." The method was developed by Mro H.D.
    [Show full text]
  • Tuning Drug Release from Polyoxazoline-Drug Conjugates T ⁎ J
    European Polymer Journal 120 (2019) 109241 Contents lists available at ScienceDirect European Polymer Journal journal homepage: www.elsevier.com/locate/europolj Tuning drug release from polyoxazoline-drug conjugates T ⁎ J. Milton Harrisa, ,1, Michael D. Bentleya, Randall W. Moreaditha, Tacey X. Viegasa,1, Zhihao Fanga, Kunsang Yoona, Rebecca Weimera, Bekir Dizmanb, Lars Nordstiernac a Serina Therapeutics, Inc., 601 Genome Way, Suite 2001, Huntsville, AL 35806, USA2 b Sabanci University, Faculty of Engineering and Natural Sciences, Tuzla, 34956 İstanbul, Turkey2 c Department of Chemistry and Chemical Engineering, Chalmers University of Technology, SE-412 96 Göteborg, Sweden ARTICLE INFO ABSTRACT Keywords: Poly(2-oxazoline)-drug conjugates with drugs attached via releasable linkages are being developed for drug Poly(2-oxazoline) or POZ delivery. Such conjugates with pendent ester linkages that covalently bind drugs to the polymer backbone ex- Poly(2-ethyl-2-oxazoline) or PEOZ hibit significantly slower hydrolytic release rates in plasma than the corresponding PEG- and dextran-drug Pendent drugs conjugates. The slow drug release rates in-vitro of these POZ-drug conjugates contribute to extended in-vivo Degradable ester linkages pharmacokinetic profiles. In some instances, the release kinetics may be relatively sustained and ideal foronce-a- Pharmacokinetics week subcutaneous injection, whereas the native drug by itself may only have an in-vivo half-life of a few hours. Drug delivery Phenolic drugs The origin of this unusual kinetic and pharmacokinetic behavior is proposed here to involve folding of the POZ conjugate such that the relatively hydrophobic drug forms a central core, and the relatively hydrophilic polymer wraps around the core and slows enzymatic attack on the drug-polymer chemical linkage.
    [Show full text]
  • Cannabis, the Endocannabinoid System and Immunity—The Journey from the Bedside to the Bench and Back
    International Journal of Molecular Sciences Review Cannabis, the Endocannabinoid System and Immunity—The Journey from the Bedside to the Bench and Back Osnat Almogi-Hazan * and Reuven Or Laboratory of Immunotherapy and Bone Marrow Transplantation, Hadassah Medical Center, The Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 91120, Israel; [email protected] * Correspondence: [email protected] Received: 21 May 2020; Accepted: 19 June 2020; Published: 23 June 2020 Abstract: The Cannabis plant contains numerous components, including cannabinoids and other active molecules. The phyto-cannabinoid activity is mediated by the endocannabinoid system. Cannabinoids affect the nervous system and play significant roles in the regulation of the immune system. While Cannabis is not yet registered as a drug, the potential of cannabinoid-based medicines for the treatment of various conditions has led many countries to authorize their clinical use. However, the data from basic and medical research dedicated to medical Cannabis is currently limited. A variety of pathological conditions involve dysregulation of the immune system. For example, in cancer, immune surveillance and cancer immuno-editing result in immune tolerance. On the other hand, in autoimmune diseases increased immune activity causes tissue damage. Immuno-modulating therapies can regulate the immune system and therefore the immune-regulatory properties of cannabinoids, suggest their use in the therapy of immune related disorders. In this contemporary review, we discuss the roles of the endocannabinoid system in immunity and explore the emerging data about the effects of cannabinoids on the immune response in different pathologies. In addition, we discuss the complexities of using cannabinoid-based treatments in each of these conditions.
    [Show full text]
  • Annual Report © 2018 Ciberned
    2018 ANNUAL REPORT © 2018 CIBERNED Coordination and management of content: Miguel Medina Padilla José de Arriba-Enríquez Aina Frontera Sánchez Almudena Flores Junquera Soledad Valero Rodríguez Design and editorial coordination: OnAccent.com CIBERNED 2018 ANNUAL REPORT INDEX 005 | Letter from the Scientific Director 006 | Introduction 009 | Aims 010 | Directory of research groups and associated institutions 012 | Geographic distribution of CIBERNED research groups 013 | Organizational structure 014 | Organization chart 015 | External scientific advisory committee 016 | Consortium members 017 | Research programmes 019 | Program 1: Alzheimer’s disease and other degenerative dementias 107 | Program 2: Parkinson’s and Huntington’s disease and other degenerative movement disorders 219 | Program 3: Amyotrophic Lateral Sclerosis and other neuromuscular disorders 257 | Cooperative research 279 | International relations 291 | Scientific productivity and other activities 307 | Finantial report 333 | Index of investigators 3 4 CIBERNED 2018 ANNUAL REPORT Jesús Ávila de Grado SCIENTIFIC DIRECTOR LETTER FROM THE SCIENTIFIC DIRECTOR As in previous years, I would like to begin by highlighting the excellent work of the re- search groups that make up CIBERNED and that has allowed us, once again, to be at the forefront of the Centers in biomedical research regarding the quality of publications in high- impact index scientific journals. In order to carry out this work, we have counted on the help and collaboration of the Management Office and the Steering Committee of the Center, as well as its support staff, and the help of the Carlos III Institute of Health and the Associated Institutions. A very important novelty has been the incorporation of six new research groups to CIBERNED, led by Drs.
    [Show full text]
  • The Use of Cannabinoids in Animals and Therapeutic Implications for Veterinary Medicine: a Review
    Veterinarni Medicina, 61, 2016 (3): 111–122 Review Article doi: 10.17221/8762-VETMED The use of cannabinoids in animals and therapeutic implications for veterinary medicine: a review L. Landa1, A. Sulcova2, P. Gbelec3 1Faculty of Medicine, Masaryk University, Brno, Czech Republic 2Central European Institute of Technology, Masaryk University, Brno, Czech Republic 3Veterinary Hospital and Ambulance AA Vet, Prague, Czech Republic ABSTRACT: Cannabinoids/medical marijuana and their possible therapeutic use have received increased atten- tion in human medicine during the last years. This increased attention is also an issue for veterinarians because particularly companion animal owners now show an increased interest in the use of these compounds in veteri- nary medicine. This review sets out to comprehensively summarise well known facts concerning properties of cannabinoids, their mechanisms of action, role of cannabinoid receptors and their classification. It outlines the main pharmacological effects of cannabinoids in laboratory rodents and it also discusses examples of possible beneficial use in other animal species (ferrets, cats, dogs, monkeys) that have been reported in the scientific lit- erature. Finally, the article deals with the prospective use of cannabinoids in veterinary medicine. We have not intended to review the topic of cannabinoids in an exhaustive manner; rather, our aim was to provide both the scientific community and clinical veterinarians with a brief, concise and understandable overview of the use of cannabinoids in veterinary
    [Show full text]
  • Pharmacodynamics of Cannabinoids
    Open Access Archives of Pharmacy and Pharmaceutical Sciences Review Article Pharmacodynamics of cannabinoids Alexandra Sulcova* ISSN ICCI - International Cannabis and Cannabinoids Institute, Jachymova 26/2, 110 00 Praha, 2639-992X Czech Republic “Pharmacodynamics of cannabinoids “(i.e. a set of biological effects elicited in the *Address for Correspondence: Alexandra Sulcova, M.D, Ph.D, Professor of Pharmacology, living organism by interaction with its biochemical and biophysical functions up to the FCMA, FECNP, FCINP, ICCI - International cellular level) is studied for a long time during both, physiological and pathological Cannabis and Cannabinoids Institute, Jachymova conditions. Cannabinoids received their names according to their natural occurrence 26/2, 110 00 Praha, Czech Republic, Tel: 420 732167678; Email: [email protected] as constituents of Cannabis sativa L. (marijuana). The species was classiied in the “Linnaeus’s Species Plantarum (1753)”, the word “sativa” means things that are Submitted: 12 April 2019 Approved: 07 May 2019 cultivated [1]. For ages, people have used cannabis-based preparations for healing and Published: 08 May 2019 pain suppression until the discovery (in 1897) of aspirin (acetylsalicylic acid) which contemporary medicine uses until today. Chemical investigation of marijuana conirmed Copyright: © 2019 Sulcova A. This is an open access article distributed under the Creative various cannabinoid-type components called cannabinoids (presently estimated at Commons Attribution License, which permits about 150). Regarding their possible pharmacodynamic effects, tetrahydrocannabinol unrestricted use, distribution, and reproduction (THC) and cannabidiol (CBD) are the most explored. The determination of THC structure in any medium, provided the original work is properly cited by means of nuclear magnetic resonance imaging increased sharply the number of professional scientiic reports dealing with the studies of THC pharmacodynamic mechanisms of action [2].
    [Show full text]
  • Icrs2015 Programme
    TH 25 ANNUAL SYMPOSIUM OF THE INTERNATIONAL CANNABINOID RESEARCH SOCIETY WOLFVILLE NOVA SCOTIA JUNE 28 - JULY 3, 2015 TH 25 ANNUAL SYMPOSIUM OF THE INTERNATIONAL CANNABINOID RESEARCH SOCIETY WOLFVILLE JUNE 28 – JULY 3, 2015 Symposium Programming by Cortical Systematics LLC Copyright © 2015 International Cannabinoid Research Society Research Triangle Park, NC USA ISBN: 978-0-9892885-2-1 These abstracts may be cited in the scientific literature as follows: Author(s), Abstract Title (2015) 25th Annual Symposium on the Cannabinoids, International Cannabinoid Research Society, Research Triangle Park, NC, USA, Page #. Funding for this conference was made possible in part by grant 5R13DA016280-13 from the National Institute on Drug Abuse. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government. Sponsors ICRS Government Sponsors National Institute on Drug Abuse Non- Profit Organization Sponsors Kang Tsou Memorial Fund 2015 ICRS Board of Directors Executive Director Cecilia Hillard, Ph.D. President Stephen Alexander, Ph.D. President- Elect Michelle Glass, Ph.D. Past President Ethan Russo, M.D. Secretary Steve Kinsey, Ph.D. Treasurer Mary Abood, Ph.D. International Secretary Roger Pertwee, D . Phil. , D . S c. Student Representative Tiffany Lee, Ph.D. Grant PI Jenny Wiley, Ph.D. Managing Director Jason Schechter, Ph.D. 2015 Symposium on the Cannabinoids Conference Coordinators Steve Alexander, Ph.D. Cecilia Hillard, Ph.D. Mary Lynch, M.D. Jason Schechter, Ph.D.
    [Show full text]
  • NIDA Drug Supply Program Catalog, 25Th Edition
    RESEARCH RESOURCES DRUG SUPPLY PROGRAM CATALOG 25TH EDITION MAY 2016 CHEMISTRY AND PHARMACEUTICS BRANCH DIVISION OF THERAPEUTICS AND MEDICAL CONSEQUENCES NATIONAL INSTITUTE ON DRUG ABUSE NATIONAL INSTITUTES OF HEALTH DEPARTMENT OF HEALTH AND HUMAN SERVICES 6001 EXECUTIVE BOULEVARD ROCKVILLE, MARYLAND 20852 160524 On the cover: CPK rendering of nalfurafine. TABLE OF CONTENTS A. Introduction ................................................................................................1 B. NIDA Drug Supply Program (DSP) Ordering Guidelines ..........................3 C. Drug Request Checklist .............................................................................8 D. Sample DEA Order Form 222 ....................................................................9 E. Supply & Analysis of Standard Solutions of Δ9-THC ..............................10 F. Alternate Sources for Peptides ...............................................................11 G. Instructions for Analytical Services .........................................................12 H. X-Ray Diffraction Analysis of Compounds .............................................13 I. Nicotine Research Cigarettes Drug Supply Program .............................16 J. Ordering Guidelines for Nicotine Research Cigarettes (NRCs)..............18 K. Ordering Guidelines for Marijuana and Marijuana Cigarettes ................21 L. Important Addresses, Telephone & Fax Numbers ..................................24 M. Available Drugs, Compounds, and Dosage Forms ..............................25
    [Show full text]
  • Table of Natural Cannabinoids
    Table of Natural Cannabinoids Scientific research continues to develop and further identify individual cannabinoids in cannabis strains and how they affect symptoms of illnesses suffered by patients. The table below identifies the chemical properties of the natural cannabinoids found in the average strains of cannabis. Levels of each of these chemicals will vary with varietal strain, growing method, and plant age. Individual cannabinoids can be enhanced or eliminated depending on need. Cannabigerol- type (CBG) Cannabigerol Cannabigerol Cannabigerovarin (E)-CBG-C monomethyl (E)-CBGV-C 5 Cannabinerolic 3 ether acid A (E)-CBGM-C 5 (Z)-CBGA-C A A 5 Cannabigerolic Cannabigerolic Cannabigerovarinic acid acid A acid A A (E)-CBGA-C5 A monomethyl (E)-CBGVA-C3 A ether (E)-CBGAM- C5 A Cannabichrom ene-type (CBC) (±)- (±)- Cannabichromen (±)- Cannabivarichromene, (±)- e Cannabichrome (±)- Cannabichrome CBC-C5 nic acid A Cannabichromevarin varinic CBCA-C5 A CBCV-C3 acid A CBCVA-C3 A Cannabidiol- type (CBD) 1 | Page (−)-Cannabidiol Cannabidiol Cannabidiol-C4 (−)- Cannabidiorc CBD-C5 momomethyl CBD-C4 Cannabidivarin ol ether CBDV-C3 CBD-C1 CBDM-C5 Cannabidiolic Cannabidivarini acid c acid CBDA-C5 CBDVA-C3 Cannabinodiol- type (CBND) Cannabinodiol Cannabinodivar CBND-C5 in CBND-C3 Tetrahydrocan nabinol-type (THC) 9 9 9 Δ - Δ - Δ - Δ9- Tetrahydrocanna Tetrahydrocan Tetrahydrocannabivarin 9 Tetrahydrocan binol nabinol-C4 Δ -THCV-C3 9 9 nabiorcol Δ -THC-C5 Δ -THC-C4 9 Δ -THCO-C1 9 9 Δ -Tetrahydro- Δ9-Tetrahydro- Δ -Tetrahydro- Δ9-Tetrahydro- cannabinolic
    [Show full text]